This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xie, D. Articles by Koeffler, H. P. Search for Related Content PubMed PubMed Citation Articles by Xie, D. Articles by Koeffler, H. P.

Levels of Expression of CYR61 and CTGF Are Prognostic for Tumor Progression and Survival of Individuals with Gliomas

¹ Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California-Los Angeles (UCLA) School of Medicine, ² Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, UCLA School of Medicine, and ³ Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, and ⁴ Institute for Nutritional Sciences, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China

The biological properties of CCN proteins include stimulation of cell proliferation, migration, and adhesion, as well as angiogenesis and tumorigenesis. We quantified CYR61, CTGF, WISP-1, and NOV mRNA expression levels in samples from sixty-six primary gliomas and five normal brain samples using quantitative real-time PCR assay. Statistical analysis was performed to explore the links between expression of the CCN genes and clinical and pathological parameters. Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively. Interestingly, significant associations were found between CYR61 expression versus tumor grade, pathology, gender, and age at diagnosis. Also, a significant correlation existed between CTGF mRNA levels versus tumor grade, gender, and pathology. In contrast to CYR61 and CTGF, no significant association was found between expression of either WISP-1 or NOV versus any of the pathological features. Furthermore, Cox regression analysis showed that CYR61 and CTGF expression had a significant correlation with patient survival. These results suggest that CYR61 and CTGF may play a role in the progression of gliomas; their levels at diagnosis may have prognostic significance; and these proteins might serve as valuable targets for therapeutic intervention.

This article has been cited by other articles:

				L. Ying, A. Lau, C. M. Alvira, R. West, G. M. Cann, B. Zhou, C. Kinnear, E. Jan, P. Sarnow, M. Van de Rijn, et al. LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor J. Cell Sci., May 1, 2009; 122(9): 1441 - 1451. [Abstract] [Full Text] [PDF]

				M.-Y. Wang, P.-S. Chen, E. Prakash, H.-C. Hsu, H.-Y. Huang, M.-T. Lin, K.-J. Chang, and M.-L. Kuo Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1 Cancer Res., April 15, 2009; 69(8): 3482 - 3491. [Abstract] [Full Text] [PDF]

				M. Hirschfeld, A. zur Hausen, H. Bettendorf, M. Jager, and E. Stickeler Alternative Splicing of Cyr61 Is Regulated by Hypoxia and Significantly Changed in Breast Cancer Cancer Res., March 1, 2009; 69(5): 2082 - 2090. [Abstract] [Full Text] [PDF]

				K. L. Bennewith, X. Huang, C. M. Ham, E. E. Graves, J. T. Erler, N. Kambham, J. Feazell, G. P. Yang, A. Koong, and A. J. Giaccia The Role of Tumor Cell-Derived Connective Tissue Growth Factor (CTGF/CCN2) in Pancreatic Tumor Growth Cancer Res., February 1, 2009; 69(3): 775 - 784. [Abstract] [Full Text] [PDF]

				C. T. Walsh, J. Radeff-Huang, R. Matteo, A. Hsiao, S. Subramaniam, D. Stupack, and J. H. Brown Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61 FASEB J, November 1, 2008; 22(11): 4011 - 4021. [Abstract] [Full Text] [PDF]

				H. Alvarez, A. Corvalan, J. C. Roa, P. Argani, F. Murillo, J. Edwards, R. Beaty, G. Feldmann, S.-M. Hong, M. Mullendore, et al. Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2631 - 2638. [Abstract] [Full Text] [PDF]

				Y.-Z. Deng, P.-P. Chen, Y. Wang, D. Yin, H. P. Koeffler, B. Li, X.-J. Tong, and D. Xie Connective Tissue Growth Factor Is Overexpressed in Esophageal Squamous Cell Carcinoma and Promotes Tumorigenicity through -Catenin-T-cell Factor/Lef Signaling J. Biol. Chem., December 14, 2007; 282(50): 36571 - 36581. [Abstract] [Full Text] [PDF]

				O. Sala-Torra, H. M. Gundacker, D. L. Stirewalt, P. A. Ladne, E. L. Pogosova-Agadjanyan, M. L. Slovak, C. L. Willman, S. Heimfeld, D. H. Boldt, and J. P. Radich Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia Blood, April 1, 2007; 109(7): 3080 - 3083. [Abstract] [Full Text] [PDF]

				N. Auger, J. Thillet, K. Wanherdrick, A. Idbaih, M.-E. Legrier, B. Dutrillaux, M. Sanson, and M.-F. Poupon Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol. Cancer Ther., September 1, 2006; 5(9): 2182 - 2192. [Abstract] [Full Text] [PDF]

				W. Chien, D. Yin, D. Gui, A. Mori, J. M. Frank, J. Said, D. Kusuanco, A. Marchevsky, R. McKenna, and H. P. Koeffler Suppression of Cell Proliferation and Signaling Transduction by Connective Tissue Growth Factor in Non-Small Cell Lung Cancer Cells Mol. Cancer Res., August 1, 2006; 4(8): 591 - 598. [Abstract] [Full Text] [PDF]

				C.-C. Chang, M.-T. Lin, B.-R. Lin, Y.-M. Jeng, S.-T. Chen, C.-Y. Chu, R. J. Chen, K.-J. Chang, P.-C. Yang, and M.-L. Kuo Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst, July 19, 2006; 98(14): 984 - 995. [Abstract] [Full Text] [PDF]

				N. Dornhofer, S. Spong, K. Bennewith, A. Salim, S. Klaus, N. Kambham, C. Wong, F. Kaper, P. Sutphin, R. Nacalumi, et al. Connective Tissue Growth Factor-Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis Cancer Res., June 1, 2006; 66(11): 5816 - 5827. [Abstract] [Full Text] [PDF]

				T. Aikawa, J. Gunn, S. M. Spong, S. J. Klaus, and M. Korc Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1108 - 1116. [Abstract] [Full Text] [PDF]

				U. R. Pendurthi, T. T. Tran, M. Post, and L. V. M. Rao Proteolysis of CCN1 by Plasmin: Functional Implications Cancer Res., November 1, 2005; 65(21): 9705 - 9711. [Abstract] [Full Text] [PDF]

				M. Bredel, C. Bredel, D. Juric, G. R. Harsh, H. Vogel, L. D. Recht, and B. I. Sikic Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas Cancer Res., October 1, 2005; 65(19): 8679 - 8689. [Abstract] [Full Text] [PDF]

				Y. Jin, H. P. Kim, E. Ifedigbo, L. F. Lau, and A. M. K. Choi Cyr61 Protects against Hyperoxia-Induced Cell Death via Akt Pathway in Pulmonary Epithelial Cells Am. J. Respir. Cell Mol. Biol., September 1, 2005; 33(3): 297 - 302. [Abstract] [Full Text] [PDF]

				M.-T. Lin, C.-Y. Zuon, C.-C. Chang, S.-T. Chen, C.-P. Chen, B.-R. Lin, M.-Y. Wang, Y.-M. Jeng, K.-J. Chang, P.-H. Lee, et al. Cyr61 Induces Gastric Cancer Cell Motility/Invasion via Activation of the Integrin/Nuclear Factor-{kappa}B/Cyclooxygenase-2 Signaling Pathway Clin. Cancer Res., August 15, 2005; 11(16): 5809 - 5820. [Abstract] [Full Text] [PDF]

				M. Hagedorn, S. Javerzat, D. Gilges, A. Meyre, B. de Lafarge, A. Eichmann, and A. Bikfalvi Accessing key steps of human tumor progression in vivo by using an avian embryo model PNAS, February 1, 2005; 102(5): 1643 - 1648. [Abstract] [Full Text] [PDF]

				D. F. Higgins, M. P. Biju, Y. Akai, A. Wutz, R. S. Johnson, and V. H. Haase Hypoxic induction of Ctgf is directly mediated by Hif-1 Am J Physiol Renal Physiol, December 1, 2004; 287(6): F1223 - F1232. [Abstract] [Full Text] [PDF]